4.6 Review

Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine

Journal

EXPERIMENTAL HEMATOLOGY & ONCOLOGY
Volume 7, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s40164-018-0122-9

Keywords

Organoids; Development; Infectious diseases; Genetic diseases; Cancer; Drug development; Precision medicine; Regeneration medicine

Funding

  1. National Natural Science Foundation of China [81572608, 81874120, 81672984]
  2. Wuhan Science and Technology Bureau [2017060201010170]

Ask authors/readers for more resources

Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available